Chen Sheng, Wu Haijian, Klebe Damon, Hong Yuan, Zhang Jianmin
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China.
Neurochem Res. 2014 Sep;39(9):1621-33. doi: 10.1007/s11064-014-1241-2. Epub 2014 Jan 31.
Acute central nervous system (CNS) injuries, including stroke, traumatic brain injury (TBI), and spinal cord injury (SCI), are common causes of human disabilities and deaths, but the pathophysiology of these diseases is not fully elucidated and, thus, effective pharmacotherapies are still lacking. Valproic acid (VPA), an inhibitor of histone deacetylation, is mainly used to treat epilepsy and bipolar disorder with few complications. Recently, the neuroprotective effects of VPA have been demonstrated in several models of acute CNS injuries, such as stroke, TBI, and SCI. VPA protects the brain from injury progression via anti-inflammatory, anti-apoptotic, and neurotrophic effects. In this review, we focus on the emerging neuroprotective properties of VPA and explore the underlying mechanisms. In particular, we discuss several potential related factors in VPA research and present the opportunity to administer VPA as a novel neuropective agent.
急性中枢神经系统（CNS）损伤，包括中风、创伤性脑损伤（TBI）和脊髓损伤（SCI），是人类致残和死亡的常见原因，但这些疾病的病理生理学尚未完全阐明，因此仍然缺乏有效的药物治疗方法。丙戊酸（VPA）是一种组蛋白去乙酰化抑制剂，主要用于治疗癫痫和双相情感障碍，且并发症较少。最近，VPA的神经保护作用已在几种急性CNS损伤模型中得到证实，如中风、TBI和SCI。VPA通过抗炎、抗凋亡和神经营养作用保护大脑免受损伤进展。在这篇综述中，我们重点关注VPA新出现的神经保护特性，并探讨其潜在机制。特别是，我们讨论了VPA研究中的几个潜在相关因素，并提出了将VPA作为一种新型神经保护剂给药的机会。
Zotero 插件